Copyright
©The Author(s) 2022.
World J Gastroenterol. Sep 28, 2022; 28(36): 5280-5299
Published online Sep 28, 2022. doi: 10.3748/wjg.v28.i36.5280
Published online Sep 28, 2022. doi: 10.3748/wjg.v28.i36.5280
Figure 5 Summary of studies applying nanoparticle platforms in alcohol-associated liver disease.
A graphical summary of nanoparticle platforms which to date have been applied for the treatment or prevention of alcohol-associated liver disease in rodent models. Arrows represent organ targets of each platform. Example cargoes used in research articles discussed in this review are listed next to each platform. Current limitations of the field are described on the lower right. AAV8: Adeno-associated virus serotype 8; HSCs: Hepatic stellate cells; IL-22: Interleukin 22; KCs: Kupffer cells; miRNA: Micro-RNA; PCX: Polycationic CXCR4 antagonists; S-ODN: Antisense phosphorothioate oligodeoxynucleotide.
- Citation: Warner JB, Guenthner SC, Hardesty JE, McClain CJ, Warner DR, Kirpich IA. Liver-specific drug delivery platforms: Applications for the treatment of alcohol-associated liver disease. World J Gastroenterol 2022; 28(36): 5280-5299
- URL: https://www.wjgnet.com/1007-9327/full/v28/i36/5280.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i36.5280